Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

导出 OA

翻译打印收藏纠错

作者： Michael G,Ison ^[1] ; Frederick G,Hayden ^[2] ; Alan J,Hay ^[3] ; Larisa V,Gubareva ^[4] ; Elena A,Govorkova ^[5] ; Emi,Takashita ^[6] ; Jennifer L,McKimm-Breschkin ^[7]

作者单位： Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Electronic address: mgison@northwestern.edu. ^[1] Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, VA, USA. Electronic address: fgh@virginia.edu. ^[2] The Francis Crick Institute, London, UK. Electronic address: Alan.Hay@crick.ac.uk. ^[3] Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: LGubareva@cdc.gov. ^[4] Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: Elena.Govorkova@stjude.org. ^[5] National Institute of Infectious Diseases, Tokyo, Japan. Electronic address: emitaka@nih.go.jp. ^[6] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia. Electronic address: jmbvirology@gmail.com. ^[7]

关键词 Antiviral Baloxavir Drug resistance Fitness Influenza virus Polymerase inhibitor